MAPT and Alzheimer disease: Mook-Jung and collaborators reported the discovery of CDK-504 (Choi et al., 2020), a selective histone-deacetylase 6 inhibitor, which dramatically enhances the proteasome degradation pathway of pathological tau in AD patient-derived brain organoids and rescues synaptic deficits.